If Philip Morris International was on your watchlist instead of in your portfolio, the return may sting a little. Holding Philip Morris International from the start of the year would have returned 33.6%, including dividends. That outcome invites a simple question. Back on 1 January 2026, when analysts were arguing over whether smoke free products could truly reshape PMI’s mix and margins, what signals in that debate might have helped you judge the strength of that shift?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
The easy part of this move is behind Philip Morris International. Zero in on 33 high quality undervalued stocks for companies trading below our estimates.
The Two Philip Morris International Stories Investors Had To Weigh
The shares cost US$160 at the start of the period, and Philip Morris International sat between two very different but credible stories.
The bull narrative put fair value at US$190, 19% above the start price. It leaned on smoke free products, assuming 8.2% annual revenue growth and a future P/E of 25.7x as IQOS, ZYN, and VEEV broadened the customer base.
The bear case pointed to a fair value of US$151, 6% below the start price. It focused on intensifying public health pressure and heavier regulation as the key risks that could limit future earnings power.
What The Evidence Did To The Philip Morris International Narratives
Regulatory news set the tone. FDA modified risk status for ZYN and renewed authorization for IQOS, which backed the bullish claim that smoke free products could reshape Philip Morris International’s mix and pricing power. At the same time, Q3 2026 figures showed revenue at US$11,438m and net income at US$3,305m, with net margin slipping to 28.9%. The evidence cut both ways.
The whole debate turned on one assumption: Could higher margin smoke free products improve profitability, not just sales mix? When you assess another stock, track the net margin line against management’s product pivot claims and see whether the new category affects earnings quality over time.
What Philip Morris International’s Price Already Assumes
Philip Morris International now trades at US$209 after a 33.6% gain from the start of the year. The selected Narrative puts its Fair Value below that level, framing today’s quote as paying up for a business where smoke free momentum is already heavily reflected in the tag.
The essential question for you is what must keep going right for that to hold. A buyer at today’s price has to judge whether smoke free growth, regulatory outcomes and execution in the U.S. can sustain earnings strength without slipping against what the Narrative currently builds in.
"The numbers indicate that Philip Morris International’s current valuation and growth profile are broadly aligned, with the share price already reflecting expectations for continued smoke free expansion, solid combustible pricing and ongoing dividend progression."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Find Your Own Contrarian Opportunity
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
- Company 1 - 30% below our estimate - sells software and cloud services where AI workloads and subscriptions share infrastructure for customers.
- Company 2 - 35% below our estimate - secures subsea contracts that pair faster tieback projects with extended services and maintenance work.
- Company 3 - 48% below our estimate - converts a record backlog of complex data center builds into higher value installation projects.
Those are three of them. See all 24 companies with the balance sheet to back it up →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com